![M. Wilsey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
M. Wilsey
Voorzitter bij
SAREPTA THERAPEUTICS, INC.
Vermogen: 5 M $ op 31-05-2026
Profiel
Dr. M. K. Wilsey is voorzitter bij MiMedx Group, Inc., onafhankelijk bestuurder bij IGM Biosciences, Inc. en voorzitter bij Sarepta Therapeutics, Inc. Zij zit in de Raad van Bestuur van IGM Biosciences, Inc. Dr. Wilsey was voorheen werkzaam als Onafhankelijk Bestuurder bij Amylin Pharmaceuticals, Inc., als President & Chief Executive Officer bij KEW Group, Inc., als Lid bij de President's Council of Advisors on Science & Technology, als Director-Science, Technology & Economic Policy bij The National Research Council, als Managing Director bij RS Investment Management Co. LLC, een voorzitter en voorzitter van de National Venture Capital Association, een algemeen directeur en partner van Robertson Stephens & Co, en mede-oprichter van de Coalition for 21st Century Medicine. Zij was ook lid van de raad van bestuur van Abgenix, Inc. Zij behaalde haar doctoraatsdiploma aan de Universiteit van Californië in Davis en haar doctoraatsdiploma aan de Universiteit van Californië in Davis.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-06-2026 | 224.357 ( 0,21% ) | 4 M $ | 31-05-2026 | |
MIMEDX GROUP, INC. 0,14% | 18-06-2025 | 212.771 ( 0,14% ) | 782 997 $ | 31-05-2026 |
Actieve functies van M. Wilsey
| Bedrijven | Functie | Begin |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Voorzitter | 16-04-2015 |
| MIMEDX GROUP, INC. | Voorzitter | 19-06-2019 |
Eerdere bekende functies van M. Wilsey
| Bedrijven | Functie | Einde |
|---|---|---|
| IGM BIOSCIENCES, INC. | Directeur/Bestuurslid | 14-08-2025 |
Kew, Inc.
 Kew, Inc. Medical/Nursing ServicesHealth Services Provides oncology services | Algemeen Directeur | - |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Directeur/Bestuurslid | 08-08-2012 |
RS Investment Management Co. LLC
 RS Investment Management Co. LLC Investment ManagersFinance RS Investments provides investment advice to separately managed accounts and pooled investment vehicles across a range of investment strategies and styles. The firm offers value strategies, growth strategies, emerging markets, and international developed markets. In addition, they oversee the management of various fixed income strategies and a natural resources strategy (offered through the RS mutual funds). Sub-advisers manage the day-to-day investment programs of these strategies. | Corporate Officer/Principal | 01-12-2009 |
President's Council of Advisors on Science & Technology
 President's Council of Advisors on Science & Technology General GovernmentGovernment Provides the Administration services to science and technology | Corporate Officer/Principal | 01-01-2009 |
Opleiding van M. Wilsey
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
76
Eerstegraads connecties
13
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 13 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Sarepta Therapeutics, Inc.
 Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Abgenix, Inc.
 Abgenix, Inc. BiotechnologyHealth Technology Develops therapeutic products | Health Technology |
RS Investment Management Co. LLC
RS Investment Management Co. LLC Investment ManagersFinance RS Investments provides investment advice to separately managed accounts and pooled investment vehicles across a range of investment strategies and styles. The firm offers value strategies, growth strategies, emerging markets, and international developed markets. In addition, they oversee the management of various fixed income strategies and a natural resources strategy (offered through the RS mutual funds). Sub-advisers manage the day-to-day investment programs of these strategies. | Finance |
Robertson Stephens & Co.
 Robertson Stephens & Co. Investment Banks/BrokersFinance Provides brokerage services | Finance |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Venture Capital Association
 National Venture Capital Association Miscellaneous Commercial ServicesCommercial Services Provides business association services | Commercial Services |
President's Council of Advisors on Science & Technology
President's Council of Advisors on Science & Technology General GovernmentGovernment Provides the Administration services to science and technology | Government |
MiMedx Group, Inc.
 MiMedx Group, Inc. Medical SpecialtiesHealth Technology Develops, manufactures, and markets patent protected regenerative biomaterial products and bioimplants | Health Technology |
Kew, Inc.
Kew, Inc. Medical/Nursing ServicesHealth Services Provides oncology services | Health Services |
The Coalition for 21st Century Medicine
 The Coalition for 21st Century Medicine Miscellaneous Commercial ServicesCommercial Services The Coalition for 21st Century Medicine is a collaborative organization representing diagnostic technology companies, clinical laboratories, researchers, physicians, venture capitalists, and patient advocacy groups. The non-profit company is based in Arlington, VA. It is dedicated to advancing the development, commercialization, and adoption of molecular and genomic diagnostic technologies that enable personalized medicine, improve patient outcomes, and reduce healthcare costs. The coalition engages with policymakers to shape regulatory, reimbursement, and intellectual property policies supporting innovation in diagnostic medicine, advocates for balanced regulatory frameworks, opposes burdensome regulations on laboratory-developed tests, and promotes patent predictability. It addresses issues such as patent eligibility, Medicare payment modernization, and expanded coverage for advanced diagnostic assays, and regularly submits comments, position statements, and amicus briefs to protect intellectual property rights and improve patient access. The company was founded by Howard C. Birndorf, Jeffrey N. Peterson, M. Kathleen Behrens Wilsey, Patrick F. Terry. | Commercial Services |
Board On Science Technology & Economic Policy | |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
Kies MarketScreener 
